133 results on '"Sattler, Martin"'
Search Results
2. Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity
3. Exploring the accessibility of primary health care data in Europe's COVID-19 response: developing key indicators for managing future pandemics (Eurodata study)
4. Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
5. Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications
6. Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
7. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2
8. The Role of Surgery in Pleural Mesothelioma
9. JunB is a key regulator of multiple myeloma bone marrow angiogenesis
10. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
11. Primary care indicators for disease burden, monitoring and surveillance of COVID-19 in 31 European countries: Eurodata Study
12. Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma
13. Primary care indicators for disease burden, monitoring and surveillance of COVID-19 in 31 European countries: Eurodata Study
14. General practitioners’ deprescribing decisions in older adults with polypharmacy: a case vignette study in 31 countries
15. Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations
16. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
17. Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis
18. Abstract 6248: Inhibiting β-catenin in AML by targeting DDX5
19. Supplementary Table I from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
20. Supplementary Figures 1-7 from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
21. Data from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
22. Supplementary Figure Legends from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
23. Supplementary Figures from Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R
24. Supplementary Data from Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
25. Supplementary Figure Legends from Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R
26. Data from Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R
27. Data from Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
28. Supplementary Table 2 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
29. Supplementary Figure 2 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
30. Supplementary Figure 3 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
31. Supplementary Figure 4 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
32. Data from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
33. Supplementary Table 1 from Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma
34. Supplementary Figure 1 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
35. Supplementary Table 4 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
36. Supplementary Figure 5 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
37. Supplementary Data 1-4, Table from Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1α–Dependent Pathway in Multiple Myeloma
38. Supplementary Legends and Figures 1-2 from Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma
39. Supplementary Table 1 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
40. Supplementary Table 3 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
41. A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
42. Exploring the Next Frontier in Non–Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor
43. LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer
44. The role of primary health care in long-term care facilities during the COVID-19 pandemic in 30 European countries: a retrospective descriptive study (Eurodata study)
45. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
46. Effect of tree shelters on the survival and growth of coniferous tree species in Central South Bulgaria
47. Anti‐SARS‐CoV‐2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID‐19 therapy
48. Effect of tree shelters on the survival and growth of coniferous tree species in Central South Bulgaria
49. YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4
50. Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.